Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors

Doerffel Y, Kullmann F, Lammert F, Quietzsch D, Schöfl C, Schuppert F, Weber M, Baum V, Berndt I, Weiss C, Lahner H (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 40

Pages Range: 237-238

Authors with CRIS profile

Christof Schöfl Professur für Endokrinologie

Involved external institutions

Novartis AG CH Switzerland (CH) Universitätsklinikum Essen DE Germany (DE) Klinikum Weiden DE Germany (DE) Klinikum Chemnitz DE Germany (DE) Klinikum Kassel GmbH DE Germany (DE) Universität des Saarlandes (UdS) DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE)

How to cite

APA:

Doerffel, Y., Kullmann, F., Lammert, F., Quietzsch, D., Schöfl, C., Schuppert, F.,... Lahner, H. (2017). Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors. (pp. 237-238).

MLA:

Doerffel, Y., et al. "Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors." 2017. 237-238.

BibTeX: Download